Abstract
Expression of the mammalian pyruvate kinase M (PKM) gene provides an important example of mutually exclusive splicing. We showed previously that the hnRNP proteins A1, A2 and PTB have a crucial role in this process. Here we provide evidence that concentration-dependent interactions involving a network of these proteins are sufficient to determine the outcome of PKM splicing. At high concentrations, such as those found in most cancer cells, hnRNPA1 binding to two sites in the upstream regulated exon (exon 9) orchestrates cooperative interactions leading to exon 9 exclusion. At lower concentrations, binding shifts to downstream intronic sites, such that exon 9 is included and exon 10 mainly excluded, with any mRNA including both exons degraded by nonsense-mediated decay. Together, our results provide a mechanism by which a few general factors control alternative splicing of a widely expressed transcript.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wang, E.T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008).
Pan, Q., Shai, O., Lee, L.J., Frey, B.J. & Blencowe, B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415 (2008).
Chen, M. & Manley, J.L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10, 741–754 (2009).
Cooper, T.A., Wan, L. & Dreyfuss, G. RNA and disease. Cell 136, 777–793 (2009).
David, C.J. & Manley, J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24, 2343–2364 (2010).
Cartegni, L., Chew, S.L. & Krainer, A.R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285–298 (2002).
Kashima, T. & Manley, J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34, 460–463 (2003).
Kashima, T., Rao, N. & Manley, J.L. An intronic element contributes to splicing repression in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 104, 3426–3431 (2007).
Cáceres, J.F. & Kornblihtt, A.R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18, 186–193 (2002).
David, C.J., Chen, M., Assanah, M., Canoll, P. & Manley, J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364–368 (2010).
Chen, M., David, C.J. & Manley, J.L. Tumor metabolism: hnRNP proteins get in on the act. Cell Cycle 9, 1863–1864 (2010).
Clower, C.V. et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. USA 107, 1894–1899 (2010).
Takenaka, M. et al. Isolation and characterization of the human pyruvate kinase M gene. Eur. J. Biochem. 198, 101–106 (1991).
Chen, M., Zhang, J. & Manley, J.L. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 70, 8977–8980 (2010).
Mazurek, S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969–980 (2011).
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
Christofk, H.R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 (2008).
Zerbe, L.K. et al. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol. Carcinog. 41, 187–196 (2004).
Pino, I. et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 41, 131–143 (2003).
Moran-Jones, K., Grindlay, J., Jones, M., Smith, R. & Norman, J.C. hnRNP A2 regulates alternative mRNA splicing of TP53INP2 to control invasive cell migration. Cancer Res. 69, 9219–9227 (2009).
Burd, C.G. & Dreyfuss, G. RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J. 13, 1197–1204 (1994).
Kashima, T., Rao, N., David, C.J. & Manley, J.L. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum. Mol. Genet. 16, 3149–3159 (2007).
Cartegni, L. et al. hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-binding proteins. J. Mol. Biol. 259, 337–348 (1996).
Cobianchi, F., Karpel, R.L., Williams, K.R., Notario, V. & Wilson, S.H. Mammalian heterogeneous nuclear ribonucleoprotein complex protein A1. Large-scale overproduction in Escherichia coli and cooperative binding to single-stranded nucleic acids. J. Biol. Chem. 263, 1063–1071 (1988).
Damgaard, C.K., Tange, T.O. & Kjems, J. hnRNP A1 controls HIV-1 mRNA splicing through cooperative binding to intron and exon splicing silencers in the context of a conserved secondary structure. RNA 8, 1401–1415 (2002).
Zhu, J., Mayeda, A. & Krainer, A.R. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol. Cell 8, 1351–1361 (2001).
Okunola, H.L. & Krainer, A.R. Cooperative-binding and splicing-repressive properties of hnRNP A1. Mol. Cell. Biol. 29, 5620–5631 (2009).
Xue, Y. et al. Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol. Cell 36, 996–1006 (2009).
Ule, J. et al. An RNA map predicting Nova-dependent splicing regulation. Nature 444, 580–586 (2006).
McGlincy, N.J. et al. Expression proteomics of UPF1 knockdown in HeLa cells reveals autoregulation of hnRNP A2/B1 mediated by alternative splicing resulting in nonsense-mediated mRNA decay. BMC Genomics 11, 565 (2010).
Makeyev, E.V., Zhang, J., Carrasco, M.A. & Maniatis, T. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell 27, 435–448 (2007).
Sun, S., Zhang, Z., Sinha, R., Karni, R. & Krainer, A.R. SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control. Nat. Struct. Mol. Biol. 17, 306–312 (2010).
Jones, R.B. et al. The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs. J. Biol. Chem. 276, 4158–4167 (2001).
Chang, Y.F., Imam, J.S. & Wilkinson, M.F. The nonsense-mediated decay RNA surveillance pathway. Annu. Rev. Biochem. 76, 51–74 (2007).
Blanchette, M. & Chabot, B. Modulation of exon skipping by high-affinity hnRNP A1-binding sites and by intron elements that repress splice site utilization. EMBO J. 18, 1939–1952 (1999).
Hutchison, S., LeBel, C., Blanchette, M. & Chabot, B. Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1/A2 binding sites control 5′ splice site selection in the hnRNP A1 mRNA precursor. J. Biol. Chem. 277, 29745–29752 (2002).
Yu, Y. et al. Dynamic regulation of alternative splicing by silencers that modulate 5′ splice site competition. Cell 135, 1224–1236 (2008).
McGlincy, N.J. & Smith, C.W. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem. Sci. 33, 385–393 (2008).
Fu, X.Y., Colgan, J.D. & Manley, J.L. Multiple cis-acting sequence elements are required for efficient splicing of simian virus 40 small-t antigen pre-mRNA. Mol. Cell. Biol. 8, 3582–3590 (1988).
Moore, M.J. & Sharp, P.A. Site-specific modification of pre-mRNA: the 2′-hydroxyl groups at the splice sites. Science 256, 992–997 (1992).
Ule, J., Jensen, K., Mele, A. & Darnell, R.B. CLIP: a method for identifying protein-RNA interaction sites in living cells. Methods 37, 376–386 (2005).
Jensen, K.B. & Darnell, R.B. CLIP: crosslinking and immunoprecipitation of in vivo RNA targets of RNA-binding proteins. Methods Mol. Biol. 488, 85–98 (2008).
Acknowledgements
We thank T. Kashima (The Jikei University School of Medicine) for the siRNA to hnRNPs A1 and A2, E. Rosonina for help with semiquantitative PCR assays, D. Campigli Di Giammartino for discussion regarding the RNA immunoprecipitation experiments, P. Richard for help with 5′ labeling, and members of the Manley laboratory for discussions. This work was supported by US National Institutes of Health grant R01 GM048259 (J.L.M.).
Author information
Authors and Affiliations
Contributions
M.C., C.J.D. and J.L.M. conceived the project. M.C. and J.L.M. designed the experiments. C.J.D. discussed the experiments and results and conducted the experiment depicted in Figure 6g. M.C. carried out the rest of the experiments. M.C. and J.L.M. wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8 (PDF 2327 kb)
Rights and permissions
About this article
Cite this article
Chen, M., David, C. & Manley, J. Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol 19, 346–354 (2012). https://doi.org/10.1038/nsmb.2219
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb.2219
This article is cited by
-
The Role of PKM2 in Multiple Signaling Pathways Related to Neurological Diseases
Molecular Neurobiology (2023)
-
SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis
Journal of Experimental & Clinical Cancer Research (2022)
-
Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets
Cell Death Discovery (2022)
-
Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1
Cancer & Metabolism (2021)
-
HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer
Journal of Experimental & Clinical Cancer Research (2021)